Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience
Background: Hepatoblastoma (HB) is the most common liver malignancy in children. There is no standard of care for management of relapsed/refractory HB (rrHB) and reports in the literature are limited. Objective: To describe presenting features, biology, treatment strategies, and outcomes for pediatr...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/15/3921 |
| _version_ | 1797586919973978112 |
|---|---|
| author | Katherine M. Somers Rachel Bernstein Tabbouche Alexander Bondoc Alexander J. Towbin Sarangarajan Ranganathan Greg Tiao James I. Geller |
| author_facet | Katherine M. Somers Rachel Bernstein Tabbouche Alexander Bondoc Alexander J. Towbin Sarangarajan Ranganathan Greg Tiao James I. Geller |
| author_sort | Katherine M. Somers |
| collection | DOAJ |
| description | Background: Hepatoblastoma (HB) is the most common liver malignancy in children. There is no standard of care for management of relapsed/refractory HB (rrHB) and reports in the literature are limited. Objective: To describe presenting features, biology, treatment strategies, and outcomes for pediatric patients with relapsed/refractory hepatoblastoma. Methods: An IRB-approved retrospective institutional review of patients with rrHB who presented for consultation and/or care from 2000–2019. Clinical, radiographic, and histologic data were collected from all patients. Results: Thirty subjects were identified with a median age of 19.5 months (range 3–169 months) at initial diagnosis and 32.5 months (range 12–194 months) at time of first relapse. 63% of subjects were male, 70% Caucasian, and 13% were born premature. Three subjects had a known cancer predisposition syndrome. Eight patients had refractory disease while 22 patients had relapsed disease. Average time from initial diagnosis to relapse or progression was 12.5 months. Average alpha-fetoprotein (AFP) at initial diagnosis was 601,203 ng/mL (range 121–2,287,251 ng/mL). Average AFP at relapse was 12,261 ng/mL (range 2.8–201,000 ng/mL). For patients with tumor sequencing (<i>n</i> = 17), the most common mutations were in CTNNB1 (13) and NRF2 (4). First relapse sites were lungs (<i>n</i> = 12), liver (<i>n</i> = 11) and both (<i>n</i> = 6). More than one relapse/progression occurred in 47% of subjects; 6 had ≥3 relapses. Pathology in patients with multiply relapsed disease was less differentiated including descriptions of small cell undifferentiated (<i>n</i> = 3), pleomorphic (<i>n</i> = 1), transitional liver cell tumor (<i>n</i> = 2) and HB with carcinoma features (<i>n</i> = 1). All subjects underwent surgical resection of site of relapsed disease with 7 subjects requiring liver transplantation. Overall survival was 50%. Survival was associated with use of cisplatin at relapse (78.6% with vs. 25% without, <i>p</i> = 0.012). The most common late effect was ototoxicity with at least mild sensorineural hearing loss found in 80% of subjects; 54% required hearing aids. Conclusions: Retreatment with cisplatin at the time of relapse may provide an advantage for some patients with hepatoblastoma. Multiply relapsed disease was not uncommon and not associated with a worse prognosis. Careful attention should be paid to cumulative therapy-induced toxicity while concurrently aiming to improve cure. |
| first_indexed | 2024-03-11T00:30:00Z |
| format | Article |
| id | doaj.art-0d36aff92520419b84b7066063032b18 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T00:30:00Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-0d36aff92520419b84b7066063032b182023-11-18T22:43:12ZengMDPI AGCancers2072-66942023-08-011515392110.3390/cancers15153921Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional ExperienceKatherine M. Somers0Rachel Bernstein Tabbouche1Alexander Bondoc2Alexander J. Towbin3Sarangarajan Ranganathan4Greg Tiao5James I. Geller6Division of Pediatric Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USADivision of Pediatric Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USADepartment of Pediatric and Thoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USADepartment of Radiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USADepartment of Pathology and Laboratory Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USADepartment of Pediatric and Thoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USADivision of Pediatric Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USABackground: Hepatoblastoma (HB) is the most common liver malignancy in children. There is no standard of care for management of relapsed/refractory HB (rrHB) and reports in the literature are limited. Objective: To describe presenting features, biology, treatment strategies, and outcomes for pediatric patients with relapsed/refractory hepatoblastoma. Methods: An IRB-approved retrospective institutional review of patients with rrHB who presented for consultation and/or care from 2000–2019. Clinical, radiographic, and histologic data were collected from all patients. Results: Thirty subjects were identified with a median age of 19.5 months (range 3–169 months) at initial diagnosis and 32.5 months (range 12–194 months) at time of first relapse. 63% of subjects were male, 70% Caucasian, and 13% were born premature. Three subjects had a known cancer predisposition syndrome. Eight patients had refractory disease while 22 patients had relapsed disease. Average time from initial diagnosis to relapse or progression was 12.5 months. Average alpha-fetoprotein (AFP) at initial diagnosis was 601,203 ng/mL (range 121–2,287,251 ng/mL). Average AFP at relapse was 12,261 ng/mL (range 2.8–201,000 ng/mL). For patients with tumor sequencing (<i>n</i> = 17), the most common mutations were in CTNNB1 (13) and NRF2 (4). First relapse sites were lungs (<i>n</i> = 12), liver (<i>n</i> = 11) and both (<i>n</i> = 6). More than one relapse/progression occurred in 47% of subjects; 6 had ≥3 relapses. Pathology in patients with multiply relapsed disease was less differentiated including descriptions of small cell undifferentiated (<i>n</i> = 3), pleomorphic (<i>n</i> = 1), transitional liver cell tumor (<i>n</i> = 2) and HB with carcinoma features (<i>n</i> = 1). All subjects underwent surgical resection of site of relapsed disease with 7 subjects requiring liver transplantation. Overall survival was 50%. Survival was associated with use of cisplatin at relapse (78.6% with vs. 25% without, <i>p</i> = 0.012). The most common late effect was ototoxicity with at least mild sensorineural hearing loss found in 80% of subjects; 54% required hearing aids. Conclusions: Retreatment with cisplatin at the time of relapse may provide an advantage for some patients with hepatoblastoma. Multiply relapsed disease was not uncommon and not associated with a worse prognosis. Careful attention should be paid to cumulative therapy-induced toxicity while concurrently aiming to improve cure.https://www.mdpi.com/2072-6694/15/15/3921hepatoblastomarelapsed hepatoblastomacisplatinpediatric liver tumors |
| spellingShingle | Katherine M. Somers Rachel Bernstein Tabbouche Alexander Bondoc Alexander J. Towbin Sarangarajan Ranganathan Greg Tiao James I. Geller Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience Cancers hepatoblastoma relapsed hepatoblastoma cisplatin pediatric liver tumors |
| title | Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience |
| title_full | Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience |
| title_fullStr | Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience |
| title_full_unstemmed | Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience |
| title_short | Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience |
| title_sort | retreatment with cisplatin may provide a survival advantage for children with relapsed refractory hepatoblastoma an institutional experience |
| topic | hepatoblastoma relapsed hepatoblastoma cisplatin pediatric liver tumors |
| url | https://www.mdpi.com/2072-6694/15/15/3921 |
| work_keys_str_mv | AT katherinemsomers retreatmentwithcisplatinmayprovideasurvivaladvantageforchildrenwithrelapsedrefractoryhepatoblastomaaninstitutionalexperience AT rachelbernsteintabbouche retreatmentwithcisplatinmayprovideasurvivaladvantageforchildrenwithrelapsedrefractoryhepatoblastomaaninstitutionalexperience AT alexanderbondoc retreatmentwithcisplatinmayprovideasurvivaladvantageforchildrenwithrelapsedrefractoryhepatoblastomaaninstitutionalexperience AT alexanderjtowbin retreatmentwithcisplatinmayprovideasurvivaladvantageforchildrenwithrelapsedrefractoryhepatoblastomaaninstitutionalexperience AT sarangarajanranganathan retreatmentwithcisplatinmayprovideasurvivaladvantageforchildrenwithrelapsedrefractoryhepatoblastomaaninstitutionalexperience AT gregtiao retreatmentwithcisplatinmayprovideasurvivaladvantageforchildrenwithrelapsedrefractoryhepatoblastomaaninstitutionalexperience AT jamesigeller retreatmentwithcisplatinmayprovideasurvivaladvantageforchildrenwithrelapsedrefractoryhepatoblastomaaninstitutionalexperience |